Brief: Pulse Biosciences Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
08/07/2024 13:22
July 8 (Reuters) - Pulse Biosciences Inc PLSE.O :
* PULSE BIOSCIENCES, INC. ANNOUNCES RECEIPT OF FDA
BREAKTHROUGH
DEVICE DESIGNATION FOR CELLFX® NSPFA CARDIAC SURGERY SYSTEM FOR
THE TREATMENT OF ATRIAL FIBRILLATION
* PULSE BIOSCIENCES INC - TO BEGIN PIVOTAL CLINICAL TRIAL
FOR AF
IN 2025
Source text for Eikon: ID:nBw6K6lgYa
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsBrief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System